Author
Listed:
- Ghita Hatim
(IBN Rochd University Hospital Center, Morocco)
- Tarik Chekrine
(IBN Rochd University Hospital Center, Morocco)
- Majdouline Houjami
(IBN Rochd University Hospital Center, Morocco)
- Sofia Karami
(IBN Rochd University Hospital Center, Morocco)
- Zineb Bouchbika
(IBN Rochd University Hospital Center, Morocco)
- Nadia Benchakroun
(IBN Rochd University Hospital Center, Morocco)
- Hassan Jouhadi
(IBN Rochd University Hospital Center, Morocco)
- Nezha Tawfiq
(IBN Rochd University Hospital Center, Morocco)
- Said Hilmani
(IBN Rochd University Hospital Center, Morocco)
- Mehdi Karkouri
(IBN Rochd University Hospital Center, Morocco)
- Abdelhakim Lakhdar
(IBN Rochd University Hospital Center, Morocco)
- Abdelatif Benider
(IBN Rochd University Hospital Center, Morocco)
- Souha Sahraoui
(IBN Rochd University Hospital Center, Morocco)
Abstract
Background and Objectives: Medulloblastoma are a highly malignant tumor of the central nervous system, very frequent in the childhood, but remains rare in adulthood. This study aims to analyze the frequency, clinical and therapeutic aspects of adults medulloblastomas. Methods: We retrospectively analyzed the data from the record of adult’s patients treated for medulloblastoma between between January 2000 and December 2015 in in the Radiation oncology department of the Ibn Rochd University Hospital Center. Results: The average age was 27,96 years (Range: 20-53 years). The sex ratio M/F was 4 with a clear male predominance. The most common symptom was intracranial hypertension, which was present in 22 patients, followed by headaches and cerebellar syndrome which were present in 9 patients. The tumor was mostly located in the cerebellar hemispheres with an average size of 5,75 cm. One patient had pulmonary metastasis at the time of diagnosis. Twenty-four patients had a surgical resection. Complete resection was performed in 13 patients. Thus, twenty-one patients have received craniospinal irradiation with a dose of 36 Gy followed by a boost in the posterior fossa with a total dose of 54-56 Gy. Twelve patients have received Chemotherapy. Six patients are still alive. Survival rates were 50% at 3 years, 35% at 5 years, and 30% at 10 years. Conclusion: Medulloblastoma is a devastating disease with a bad prognosis. The clinical presentation is variable and the management is multidisciplinary. Radiotherapy treatment with or without Chemotherapy play an important role in the control of the disease and recurrences avoidance. Our study illustrates the importance of treatment by radiation.
Suggested Citation
Ghita Hatim & Tarik Chekrine & Majdouline Houjami & Sofia Karami & Zineb Bouchbika & Nadia Benchakroun & Hassan Jouhadi & Nezha Tawfiq & Said Hilmani & Mehdi Karkouri & Abdelhakim Lakhdar & Abdelatif , 2022.
"Adult's Medulloblastoma,"
European Journal of Medical and Health Sciences, European Open Science, vol. 4(5), pages 44-47, September.
Handle:
RePEc:epw:ejmed0:v:4:y:2022:i:5:id:41418
DOI: 10.24018/ejmed.2022.4.5.1418
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:ejmed0:v:4:y:2022:i:5:id:41418. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support (email available below). General contact details of provider: https://eu-opensci.org/index.php/ejmed .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.